|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karantanos T, Corn PG and Thompson TC:
Prostate cancer progression after androgen deprivation therapy:
Mechanisms of castrate resistance and novel therapeutic approaches.
Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zeng H, Chen W, Zheng R, Zhang S, Ji JS,
Zou X, Xia C, Sun K, Yang Z, Li H, et al: Changing cancer survival
in China during 2003-15: A pooled analysis of 17 population-based
cancer registries. Lancet Glob Health. 6:e555–e567. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hudson SV, O'Malley DM and Miller SM:
Achieving optimal delivery of follow-up care for prostate cancer
survivors: Improving patient outcomes. Patient Relat Outcome Meas.
6:75–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goodwin JF, Kothari V, Drake JM, Zhao S,
Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, et
al: DNA-PKcs-mediated transcriptional regulation drives prostate
cancer progression and metastasis. Cancer Cell. 28:97–113. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fraile JM, Quesada V, Rodriguez D, Freije
JM and López-Otín C: Deubiquitinases in cancer: New functions and
therapeutic options. Oncogene. 31:2373–2388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salmena L and Pandolfi PP: Changing venues
for tumour suppression: Balancing destruction and localization by
monoubiquitylation. Nat Rev Cancer. 7:409–413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oosterkamp HM, Hijmans EM, Brummelkamp TR,
Canisius S, Wessels LF, Zwart W and Bernards R: USP9X
downregulation renders breast cancer cells resistant to tamoxifen.
Cancer Res. 74:3810–3820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pérez-Mancera PA, Rust AG, van der Weyden
L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R,
Aust D, Rümmele P, et al: The deubiquitinase USP9X suppresses
pancreatic ductal adenocarcinoma. Nature. 486:266–270. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thanh Nguyen H, Andrejeva D, Gupta R,
Choudhary C, Hong X, Eichhorn PJ, Loya AC and Cohen SM:
Deubiquitylating enzyme USP9× regulates hippo pathway activity by
controlling angiomotin protein turnover. Cell Discov. 2:160012016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Liu Y, Yang B, Cao H, Yang CX,
Ouyang W, Zhang SM, Yang GF, Zhou FX, Zhou YF, et al: Elevated
expression of USP9X correlates with poor prognosis in human
non-small cell lung cancer. J Thorac Dis. 7:672–679.
2015.PubMed/NCBI
|
|
12
|
Fu X, Xie W, Song X, Wu K, Xiao L, Liu Y
and Zhang L: Aberrant expression of deubiquitylating enzyme USP9X
predicts poor prognosis in gastric cancer. Clin Res Hepatol
Gastroenterol. 41:687–692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Partin AW, Kattan MW, Subong EN, Walsh PC,
Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of
prostate-specific antigen, clinical stage, and Gleason score to
predict pathological stage of localized prostate cancer. A
multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fine SW: Evolution in prostate cancer
staging: Pathology updates from AJCC 8th edition and opportunities
that remain. Adv Anat Pathol. 25:327–332. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Braunhut BL, Punnen S and Kryvenko ON:
Updates on grading and staging of prostate cancer. Surg Pathol
Clin. 11:759–774. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia D, Park JH, Jung KH, Levine H and
Kaipparettu BA: Elucidating the metabolic plasticity of cancer:
Mitochondrial reprogramming and hybrid metabolic states. Cells.
7:doi: 10.3390/cells7030021. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paupe V and Prudent J: New insights into
the role of mitochondrial calcium homeostasis in cell migration.
Biochem Biophys Res Commun. 500:75–86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou C, Wang Y, Peng J, Li C, Liu P and
Shen X: SNX10 plays a critical role in MMP9 secretion via
JNK-p38-ERK signaling pathway. J Cell Biochem. 118:4664–4671. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang CY, Chiang SF, Chen WT, Ke TW, Chen
TW, You YS, Lin CY, Chao KSC and Huang CY: HMGB1 promotes
ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance
through RAGE in colorectal cancer. Cell Death Dis. 9:10042018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wood SA, Pascoe WS, Ru K, Yamada T,
Hirchenhain J, Kemler R and Mattick JS: Cloning and expression
analysis of a novel mouse gene with sequence similarity to the
Drosophila fat facets gene. Mech Dev. 63:29–38. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toloczko A, Guo F, Yuen HF, Wen Q, Wood
SA, Ong YS, Chan PY, Shaik AA, Gunaratne J, Dunne MJ, et al:
Deubiquitinating enzyme USP9X suppresses tumor growth via LATS
kinase and core components of the hippo pathway. Cancer Res.
77:4921–4933. 2017.PubMed/NCBI
|
|
24
|
McGarry E, Gaboriau D, Rainey MD,
Restuccia U, Bachi A and Santocanale C: The deubiquitinase USP9X
maintains DNA replication fork stability and DNA damage checkpoint
responses by regulating CLASPIN during S-phase. Cancer Res.
76:2384–2393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M,
Elshimali Y, Kemp KT II, Bhat K, Haro J, et al: Aberrant
phosphorylation of SMAD4 Thr277-mediated USP9×-SMAD4 interaction by
free fatty acids promotes breast cancer metastasis. Cancer Res.
77:1383–1394. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schwickart M, Huang X, Lill JR, Liu J,
Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F,
Eastham-Anderson J, et al: Deubiquitinase USP9X stabilizes MCL1 and
promotes tumour cell survival. Nature. 463:103–107. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding X, Yang DR, Xia L, Chen B, Yu S, Niu
Y, Wang M, Li G and Chang C: Targeting TR4 nuclear receptor
suppresses prostate cancer invasion via reduction of infiltrating
macrophages with alteration of the TIMP-1/MMP2/MMP9 signals. Mol
Cancer. 14:162015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moroz A, Delella FK, Almeida R, Lacorte
LM, Fávaro WJ, Deffune E and Felisbino SL: Finasteride inhibits
human prostate cancer cell invasion through MMP2 and MMP9
downregulation. PLoS One. 8:e847572013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kato T, Fujita Y, Nakane K, Kojima T,
Nozawa Y, Deguchi T and Ito M: ETS1 promotes chemoresistance and
invasion of paclitaxel-resistant, hormone-refractory PC3 prostate
cancer cells by up-regulating MDR1 and MMP9 expression. Biochem
Biophys Res Commun. 417:966–971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
London CA, Sekhon HS, Arora V, Stein DA,
Iversen PL and Devi GR: A novel antisense inhibitor of MMP-9
attenuates angiogenesis, human prostate cancer cell invasion and
tumorigenicity. Cancer Gene Ther. 10:823–832. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang X, Yao X, Qin C, Luo P and Zhang J:
Investigation of the molecular mechanisms underlying metastasis in
prostate cancer by gene expression profiling. Exp Ther Med.
12:925–932. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clarke NW, Hart CA and Brown MD: Molecular
mechanisms of metastasis in prostate cancer. Asian J Androl.
11:57–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pollard TD and Cooper JA: Actin, a central
player in cell shape and movement. Science. 326:1208–1212. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Westermann B: Mitochondrial fusion and
fission in cell life and death. Nat Rev Mol Cell Biol. 11:872–884.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao J, Zhang J, Yu M, Xie Y, Huang Y,
Wolff DW, Abel PW and Tu Y: Mitochondrial dynamics regulates
migration and invasion of breast cancer cells. Oncogene.
32:4814–4824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pal AD, Basak NP, Banerjee AS and Banerjee
S: Epstein-Barr virus latent membrane protein-2A alters
mitochondrial dynamics promoting cellular migration mediated by
Notch signaling pathway. Carcinogenesis. 35:1592–1601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hollenbeck PJ and Saxton WM: The axonal
transport of mitochondria. J Cell Sci. 118:5411–5419. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yin M, Lu Q, Liu X, Wang T, Liu Y and Chen
L: Silencing Drp1 inhibits glioma cells proliferation and invasion
by RHOA/ROCK1 pathway. Biochem Biophys Res Commun. 478:663–668.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang J, Zhang Y, Wu W, Wang F, Liu X,
Shui G and Nie C: Guanylate-binding protein 2 regulates
Drp1-mediated mitochondrial fission to suppress breast cancer cell
invasion. Cell Death Dis. 8:e31512017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fu L, Dong Q, He J, Wang X, Xing J, Wang
E, Qiu X and Li Q: SIRT4 inhibits malignancy progression of NSCLCs,
through mitochondrial dynamics mediated by the ERK-Drp1 pathway.
Oncogene. 36:2724–2736. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kato T, Fujita Y, Nakane K, Mizutani K,
Terazawa R, Ehara H, Kanimoto Y, Kojima T, Nozawa Y, Deguchi T and
Ito M: CCR1/CCL5 interaction promotes invasion of taxane-resistant
PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and
by activating ERK and Rac signaling. Cytokine. 64:251–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cai J, Wang J, Huang Y, Wu H, Xia T, Xiao
J, Chen X, Li H, Qiu Y, Wang Y, et al: ERK/Drp1-dependent
mitochondrial fission is involved in the MSC-induced drug
resistance of T-cell acute lymphoblastic leukemia cells. Cell Death
Dis. 7:e24592016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shen G, Lin Y, Yang X, Zhang J, Xu Z and
Jia H: MicroRNA-26b inhibits epithelial-mesenchymal transition in
hepatocellular carcinoma by targeting USP9X. BMC Cancer.
14:3932014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang S, Kollipara RK, Srivastava N, Li R,
Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P,
Lotan Y, et al: Ablation of the oncogenic transcription factor ERG
by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci
USA. 111:4251–4256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H,
Dong XW, Hu YZ, Lin NM, He QJ and Yang B: Synergistic antitumor
activity of gemcitabine and ABT-737 in vitro and in vivo through
disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther.
10:1264–1275. 2011. View Article : Google Scholar : PubMed/NCBI
|
